Cargando…
Novel biomarkers for pulmonary arterial hypertension
Pulmonary arterial hypertension is a deadly disease characterized by elevated pulmonary arterial pressures leading to right ventricular hypertrophy and failure. The confirmatory gold standard test is the invasive right heart catheterization. The disease course is monitored by pulmonary artery systol...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955255/ https://www.ncbi.nlm.nih.gov/pubmed/27439993 http://dx.doi.org/10.1186/s12931-016-0396-6 |
_version_ | 1782443919800270848 |
---|---|
author | Anwar, Anjum Ruffenach, Gregoire Mahajan, Aman Eghbali, Mansoureh Umar, Soban |
author_facet | Anwar, Anjum Ruffenach, Gregoire Mahajan, Aman Eghbali, Mansoureh Umar, Soban |
author_sort | Anwar, Anjum |
collection | PubMed |
description | Pulmonary arterial hypertension is a deadly disease characterized by elevated pulmonary arterial pressures leading to right ventricular hypertrophy and failure. The confirmatory gold standard test is the invasive right heart catheterization. The disease course is monitored by pulmonary artery systolic pressure measurement via transthoracic echocardiography. A simple non-invasive test to frequently monitor the patients is much needed. Search for a novel biomarker that can be detected by a simple test is ongoing and many different options are being studied. Here we review some of the new and unique pre-clinical options for potential pulmonary hypertension biomarkers. These biomarkers can be broadly categorized based on their association with endothelial cell dysfunction, inflammation, epigenetics, cardiac function, oxidative stress, metabolism,extracellular matrix, and volatile compounds in exhaled breath condensate. A biomarker that can be detected in blood, urine or breath condensate and correlates with disease severity, progression and response to therapy may result in significant cost reduction and improved patient outcomes. |
format | Online Article Text |
id | pubmed-4955255 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-49552552016-07-22 Novel biomarkers for pulmonary arterial hypertension Anwar, Anjum Ruffenach, Gregoire Mahajan, Aman Eghbali, Mansoureh Umar, Soban Respir Res Review Pulmonary arterial hypertension is a deadly disease characterized by elevated pulmonary arterial pressures leading to right ventricular hypertrophy and failure. The confirmatory gold standard test is the invasive right heart catheterization. The disease course is monitored by pulmonary artery systolic pressure measurement via transthoracic echocardiography. A simple non-invasive test to frequently monitor the patients is much needed. Search for a novel biomarker that can be detected by a simple test is ongoing and many different options are being studied. Here we review some of the new and unique pre-clinical options for potential pulmonary hypertension biomarkers. These biomarkers can be broadly categorized based on their association with endothelial cell dysfunction, inflammation, epigenetics, cardiac function, oxidative stress, metabolism,extracellular matrix, and volatile compounds in exhaled breath condensate. A biomarker that can be detected in blood, urine or breath condensate and correlates with disease severity, progression and response to therapy may result in significant cost reduction and improved patient outcomes. BioMed Central 2016-07-20 2016 /pmc/articles/PMC4955255/ /pubmed/27439993 http://dx.doi.org/10.1186/s12931-016-0396-6 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Anwar, Anjum Ruffenach, Gregoire Mahajan, Aman Eghbali, Mansoureh Umar, Soban Novel biomarkers for pulmonary arterial hypertension |
title | Novel biomarkers for pulmonary arterial hypertension |
title_full | Novel biomarkers for pulmonary arterial hypertension |
title_fullStr | Novel biomarkers for pulmonary arterial hypertension |
title_full_unstemmed | Novel biomarkers for pulmonary arterial hypertension |
title_short | Novel biomarkers for pulmonary arterial hypertension |
title_sort | novel biomarkers for pulmonary arterial hypertension |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955255/ https://www.ncbi.nlm.nih.gov/pubmed/27439993 http://dx.doi.org/10.1186/s12931-016-0396-6 |
work_keys_str_mv | AT anwaranjum novelbiomarkersforpulmonaryarterialhypertension AT ruffenachgregoire novelbiomarkersforpulmonaryarterialhypertension AT mahajanaman novelbiomarkersforpulmonaryarterialhypertension AT eghbalimansoureh novelbiomarkersforpulmonaryarterialhypertension AT umarsoban novelbiomarkersforpulmonaryarterialhypertension |